source
- Moderna's cancer vaccine boost lifts stock, sparks talk of Keytruda-like reachModerna’s shares surged 177% after a phase 3 topline win for its Merck‑partnered cancer vaccine, intismeran autogene, was disclosed. The data, released on Wednesday, added roughly $45 billion to Mo…
- FDA approves Ultragenyx gene therapy and Regeneron ultra-rare disease drugThe Food and Drug Administration gave the green light to a gene‑therapy product from Ultragenyx, marking a new treatment option in the company’s pipeline. In a separate decision, Regeneron secured…